Clinical trials: Chronic Hepatitis, B Virus
HBeAg-Positive Chronic Hepatitis B
Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B
This is a multicenter, double blind, active-controlled, randomized, parallel group study to demonstrate the anti-viral activity and safety of Baracle Tab. and Baraclude Tab. for patients with HBeAg Chronic Hepatitis B.
- Trial name
- NCT01913431
- Testing
- Baracle Tab.®, Baraclude Tab.®
- Where
- South Korea
- Volunteers
- 118 people
- Sponsor
- Dong-A ST Co., Ltd.
Chronic Heptitis B
A Randomized Controlled Trial on the Efficacy of Tenofovir Disoproxil Fumarate (TDF)-Switch Therapy in Chronic Hepatitis B Patients With Incomplete Response to Entecavir
Currently, five nucleos(t)ide analogs are approved for the treatment of chronic hepatitis B, namely lamivudine, adefovir dipivoxil, telbivudine, entecavir (ETV) and tenofovir disoproxil fumarate (TDF).
- Trial name
- NCT01918631
- Testing
- tenofovir disoproxil fumarate, Entecavir
- Where
- Hong Kong
- Volunteers
- 36 people
- Sponsor
- Chinese University of Hong Kong
Hepatitis B, Chronic
Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection
IMC-I109V is an immune-mobilizing monoclonal T cell receptor (TCR) against viruses (ImmTAV®), a new class of bispecific protein therapeutics designed for the treatment of chronic hepatitis B virus (HBV) infection (CHB).
- Trial name
- NCT05867056
- Testing
- IMC-I109V Single Ascending Dose, IMC-I109V Multiple Ascending Doses, HBV HCC Module MAD
- Where
- 15 sites in United States, Australia and 7 more
- Sponsor
- Immunocore Ltd
Chronic Hepatitis C
HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b
Sustained virological response (SVR) to antiviral therapy in patients with chronic hepatitis C genotype 1 according to subtype (1a vs.1b) has not been extensively investigated.
- Trial name
- genotype (NCT01342003)
- Where
- Italy
- Volunteers
- 388 people
- Sponsor
- Azienda Ospedaliera San Camillo Forlanini
Liver Fibrosis
Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.
This study was a randomized, double-blind, placebo-controlled, entecavir basic treatment, multicentre clinical study. The main objective of this study was to confirm the efficacy and safety of hydronidone in the treatment of…
- Trial name
- NCT05115942
- Testing
- Hydronidone capsules
- Where
- 44 sites in China
- Volunteers
- 248 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Hepatitis B
Entecavir to TAF Switch
A research study to observe the safety, efficacy and tolerability of switching from Entecavir (ETV) to Tenofovir Alafenamide TAF in patients with chronic hepatitis B
- Trial name
- NCT03489239
- Testing
- Tenofovir Alafenamide
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Thomas Jefferson University
Chronic Hepatitis B, Late Pregnancy
Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B
The purpose of this study is to evaluate the efficacy and safety of telbivudine and lamivudine use during late pregnancy for the prevention of HBV perinatal transmission in highly viraemic mothers.
- Conditions
- Chronic Hepatitis B, Late Pregnancy, Transmission, Complication
- Trial name
- NCT01743079
- Testing
- Telbivudine, Lamivudine
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Beijing YouAn Hospital
Liver Fibrosis
A Nomogram for Evaluating Significant Liver Fibrosis in Patients With Chronic Hepatitis B Virus Infection
Liver fibrosis is the key step for progression to cirrhosis and liver cancer in patients with chronic hepatitis B (CHB). It is crucial to identify significant liver fibrosis in the treatment of CHB patients.
- Trial name
- NCT05560503
- Volunteers
- 259 people
- Sponsor
- Xiangya Hospital of Central South University
Hepatitis b & Liver Dysfunction
Study on PK of Hydronidone in Patients and Special Population
1. Evaluate the pharmacokinetic (PK) characteristics of Hydronidone capsule in target patients (patients with chronic viral hepatitis b with liver fibrosis) and special population (patients with mild liver dysfunction). 2.
- Trial name
- NCT04123769
- Testing
- Hydronidone
- Where
- China
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Chronic Hepatitis B
Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis
The purpose of this study is to determine if DNA vaccination of chronic HBV patients under treatment with NRTI can restore T-cell responsiveness and delay virologic reactivation after treatment discontinuation.
- Trial name
- VAC-ADN (NCT00536627)
- Testing
- DNA vaccine pCMVS2.S
- Where
- France
- Volunteers
- 70 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Hepatitis B
Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy
In this cohort study, patients with chronic hepatitis B who prior participated in TB1211IFN study and received at least 39 doses of peginterferon alfa will be enrolled.
- Trial name
- NCT03181113
- Testing
- Peginterferon Alfa-2B, Peginterferon Alfa-2A
- Where
- 28 sites in China
- Volunteers
- 473 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Chronic Hepatitis B
Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)
Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection. Whereas, the long-term effect of TAF to liver fibrosis is still unknown.
- Trial name
- NCT04939441
- Testing
- Tenofovir alafenamide
- Where
- 7 sites in China
- Volunteers
- 100 people
- Sponsor
- Jidong Jia
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted, Hepatitis B, Chronic
Laboratory Profile of Hepatitis B and C in Users of a Reference Service
Chronic hepatitis by the B virus (HBV) and/or by the C virus (HCV) is a major public-health problem since it presents a long phase of clinical latency which makes its early diagnosis difficult and results in the development of a…
- Trial name
- NCT00512941
- Where
- 2 sites in Brazil
- Volunteers
- 531 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Thrombocytopenia, Hepatitis B, Chronic
Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment
This study aims to investigate the efficacy and safety of avatrombopag for treating thrombocytopenia in hepatitis b virus related acute-on-chronic liver failure patients receiving artificial liver support system treatment.
- Conditions
- Thrombocytopenia, Hepatitis B, Chronic, Acute-On-Chronic Liver Failure
- Trial name
- NCT05382013
- Testing
- Avatrombopag, Artificial Liver Support System, Comprehensive internal medical treatment.
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Infant, Premature
Vitamin A Supplementation in Preterm Infants
Extremely low birth weight infants have decreased blood levels of Vitamin A. This Vitamin A deficiency may increase the risk of infections and chronic lung disease in these infants.
- Trial name
- NCT00063596
- Testing
- Vitamin A supplementation
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Chronic Hepatitis B
Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults
Patients will receive Peginterferon alfa-2a according to the standard medical practice but the observation period is 12 weeks
- Trial name
- NCT02822547
- Testing
- Peginterferon alfa-2a
- Where
- South Korea
- Volunteers
- 253 people
- Sponsor
- Yonsei University
Hepatitis B
Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy
The purpose of this study is to evaluate the efficacy and safety of generic entecavir monotherapy or in combination with adefovir for chronic hepatitis B patients with inadequate response to NUC therapy
- Trial name
- NCT01341743
- Testing
- Entecavir, Entecavir, Adefovir
- Where
- 16 sites in China
- Volunteers
- 360 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Chronic Hepatitis B
A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)
To evaluate the efficacy and safety of HRS9950 tablets in chronic hepatitis B patients who are virologically suppressed on nucleoside or nucleotide analogues (NAs).
- Trial name
- NCT05905458
- Testing
- HRS9950 tablets
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Hepatitis B
The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC
The CHB subjects who are cirrhosis, will be randomized to two groups. The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,180μg/week for 48 weeks.
- Trial name
- NCT03084250
- Testing
- Peginterferon Alfa-2A, Adefovir, entecavir,tenofovir, either of them
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Nanhui Nanhua Hospital
Chronic Hepatitis B Virus Infection
A Clinical Study of HH-006 in Untreated Chronic Hepatitis B Virus Infected Patients
This is a randomized, double-blind, placebo-controlled Phase I dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of multiple ascending doses (120 mg, 240 mg, 480 mg SC, QW×5) of…
- Trial name
- NCT07515209
- Testing
- HH-006, 0.9% normal saline
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- Huahui Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.